The oral hypoglycemics: boon or bane?

Following the UGDP study on oral hypoglycemic agents, and the Biometric Society's subsequent re-evaluation of the data, this form of therapy has been the subject of both attack and defence worldwide. This article reviews the basic findings of the UGDP study and comments on the data, following with suggestions for treatment of adult onset diabetes in the light of these findings.